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Phosphorylation of EXO1 by CDKs 1 and 2 regulates
DNA end resection and repair pathway choice
Nozomi Tomimatsu1, Bipasha Mukherjee1, Molly Catherine Hardebeck1, Mariya Ilcheva1,
Cristel Vanessa Camacho1,w, Janelle Louise Harris2, Matthew Porteus3, Bertrand Llorente4,
Kum Kum Khanna2 & Sandeep Burma1
Resection of DNA double-strand breaks (DSBs) is a pivotal step during which the choice
between NHEJ and HR DNA repair pathways is made. Although CDKs are known to control
initiation of resection, their role in regulating long-range resection remains elusive. Here
we show that CDKs 1/2 phosphorylate the long-range resection nuclease EXO1 at
four C-terminal S/TP sites during S/G2 phases of the cell cycle. Impairment of EXO1
phosphorylation attenuates resection, chromosomal integrity, cell survival and HR, but
augments NHEJ upon DNA damage. In contrast, cells expressing phospho-mimic EXO1 are
proﬁcient in resection even after CDK inhibition and favour HR over NHEJ. Mutation of cyclin-
binding sites on EXO1 attenuates CDK binding and EXO1 phosphorylation, causing a resection
defect that can be rescued by phospho-mimic mutations. Mechanistically, phosphorylation of
EXO1 augments its recruitment to DNA breaks possibly via interactions with BRCA1.
In summary, phosphorylation of EXO1 by CDKs is a novel mechanism regulating repair
pathway choice.
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T
he integrity of our genome is constantly threatened by
DNA double-strand breaks (DSBs). Two major pathways
have evolved to repair these breaks1. Non-homologous end
joining (NHEJ) is an error-prone pathway during which DNA
ends are ligated independently of a template, whereas
homologous recombination (HR) is an error-free pathway that
uses the intact sister chromatid as a template for repair. Cell cycle
regulation of these two pathways is critical for the maintenance of
genomic integrity. Suppression of HR in G1 prevents loss of
heterozygosity and chromosomal rearrangements arising from
recombination with the homologous chromosome or non-allelic
homologous loci, respectively. On the other hand, promotion of
HR in S and G2 phases ensures accurate repair, especially that of
one-ended replication fork-associated breaks. However, the
underlying mechanisms of cell cycle regulation of NHEJ and
HR pathways are not completely worked out.
Coupling DNA repair machineries to the engine that drives the
cell cycle, namely, cyclin-dependent kinases (CDKs) in complex
with their cyclin partners2, is an efﬁcient way to achieve cell cycle
regulation of DSB repair. It is becoming increasingly clear that the
CDKs that promote cell cycle progression through S and G2
phases concomitantly promote HR in these phases by activating
the ﬁrst step in recombination, viz. DNA end resection3,4. DNA
end resection in the 50–30 direction results in the formation of a
30-OH single-stranded tail that is ﬁrst coated with replication
protein A (RPA), which is then exchanged for Rad51 to form a
recombinogenic nucleoﬁlament. Resection is a key step at which
‘repair pathway choice’, the choice between NHEJ and HR, can be
enforced by the cell as the generation of single-stranded DNA
(ssDNA) would favour HR and concomitantly disfavour NHEJ by
stymieing the binding of NHEJ proteins. A ‘two-step’ model of
resection has been formulated, based mainly on studies in
yeast3,5. The ﬁrst step, ‘initiation of resection’, involves the
removal ofB50–100 bases of DNA from the 50-end by the MRX/
MRN complex (Mre11–Rad50–Xrs2 in yeast and Mre11–Rad50–
Nbs1 in humans) in conjunction with Sae2/CtBP-interacting
protein (CtIP)6–9. The second step, ‘long-range resection’, is
carried out by two alternate pathways involving the 50–30
exonuclease Exo1 on one hand, and the helicase–topoisomerase
complex Sgs1–Top3–Rmi1/BLM–TOPIIIa–RMI1-2 in concert
with the nuclease Dna2 on the other hand. The current
understanding is that CDKs control DNA end resection and
repair pathway choice by promoting the initiation of resection via
phosphorylation of Sae2/CtIP and Nbs1 (refs 10–16). Here we
describe a novel mechanism by which CDKs control repair
pathway choice in human cells that involves regulation of long-
range resection via phosphorylation of EXO1.
Results
EXO1 is phosphorylated by CDKs 1 and 2 in S and G2 phases.
We have previously shown that EXO1 plays a major role in
resection and HR in human cells17–20, making it a plausible
candidate for regulation by CDKs in a cell cycle-dependent
manner. To examine this possibility, HEK-293 cells ectopically
expressing V5-tagged EXO1 were synchronized in different
phases of the cell cycle (Supplementary Fig. 1a). EXO1 was
immunoprecipitated (IP) with anti-V5 antibody and western
blotted with anti-phospho-(Ser) or anti-phospho-(Thr) CDK
substrate antibodies. We observed that EXO1 was increasingly
phosphorylated as cells traversed the cell cycle from G1, through
S, to G2 (Fig. 1a). No increase in EXO1 phosphorylation was seen
on treating cells with ionizing radiation (IR) or ultraviolet
indicating that the increase in EXO1 phosphorylation seen with
cell cycle progression was not due to any genotoxic stress caused
by cell synchronization methods (Supplementary Fig. 1b).
Phosphorylation of EXO1 in cells synchronized in G2 was
attenuated by the CDK inhibitors AZD5438 and roscovitine21,22,
both of which inhibit CDKs 1 and 2, the principal CDKs driving
progression through S and G2 phases2 (Fig 1a,b; Supplementary
Fig. 1c). Phosphorylation of EXO1 in cells synchronized in G2
was also attenuated on short interfering RNA (siRNA)-mediated
depletion of CDKs 1 and 2 (Fig. 1c; Supplementary Fig. 1d).
Depletion of CDK 1 and/or 2 did not signiﬁcantly alter cell cycle
proﬁles (Supplementary Fig. 1e); hence, the observed reduction in
EXO1 phosphorylation was not due to a reduction in the total
population in S and G2. These observations indicated that EXO1
is hyperphosphorylated by CDKs 1 and 2 in S and G2 phases of
the cell cycle and hinted that EXO1 may be regulated by CDKs.
Human EXO1 bears 10 putative S/TP CDK phosphorylation
sites, 2 of which (T732 and S815) conform to the optimal
CDK-recognition motif, (S/T)PX(K/R)23 (Fig. 1d). To identify
S/TP sites that might be important for resection, U2OS cells
with siRNA-mediated depletion of endogenous EXO1 were
complemented with 10 different siRNA-resistant EXO1
constructs that were individually mutated to non-phospho-
rylatable Ala at each of these putative phosphorylation sites.
siRNA-resistant wild-type EXO1 (rWT-EXO1) served as a
positive control, while siRNA-sensitive wild-type EXO1 (sWT-
EXO1) and nuclease dead EXO1 bearing a D173A mutation24
(ND-EXO1) served as negative controls. Cells were screened for
resection defects by quantifying RPA foci after irradiation, as
described previously19 (see legends to Supplementary Fig. 1f–h
for description of the screen and controls). We found that
individual mutations of the four carboxy-terminal S/TP sites
(S639, T732, S815 and T824) resulted in resection defects as
evidenced by reduced numbers of RPA foci (Fig. 1e). Mutation of
all four sites to Ala (4A-EXO1) eliminated EXO1 detection by
anti-CDK substrate antibodies (Fig. 1f). However, negligible
reduction was observed with individual mutations of these four
sites probably because the anti-CDK substrate antibodies are not
site speciﬁc and would recognize multiple phosphorylated S/TP
sites on the same protein (Supplementary Fig. 1i). Therefore, to
directly demonstrate phosphorylation of speciﬁc S/TP sites
in vivo, we attempted to generate phospho-speciﬁc antibodies
against these sites, and were successful in raising antibodies to
phospho-T732 (Supplementary Fig. 1j,k). In IP-westerns, the
anti-p-T732 antibody could recognize WT-EXO1 but not the
non-phosphorylatable T732A mutant, conﬁrming the speciﬁcity
of this antibody (Fig. 1g). Phosphorylation of EXO1 at T732
was cell cycle- and CDK-dependent, with a higher level of
phosphorylation observed in G2 that was attenuated on
pretreatment of cells with the CDK inhibitor AZD5438
(Fig. 1g). Akin to V5-tagged EXO1, endogenous EXO1 in these
cells was also phosphorylated in a cell cycle- and CDK-dependent
manner (Supplementary Fig. 1l). Our results directly demonstrate
that T732 of EXO1 is phosphorylated in vivo in a cell cycle- and
CDK-dependent manner. Moreover, western blotting results with
4A-EXO1 (Fig. 1f) tentatively indicate that the other three
identiﬁed sites are also phosphorylated in S/G2 phases, a
supposition borne out by independent mass spectrometric
analyses identifying S639 and S815 of EXO1 as bona ﬁde
phosphorylation targets in vivo25–27.
Phosphorylation of EXO1 by CDKs promotes DNA end
resection. To deﬁnitively establish the role of these four sites
in regulation of DSB resection and HR, we used three com-
plementary assays involving quantiﬁcation of RPA, 5-bromo-20-
deoxyuridine (BrdU)/ssDNA and Rad51 foci, and compared foci
formation in cells expressing WT-EXO1, non-phospho-
rylatable 4A-EXO1 or phospho-mimic 4D-EXO1 (all four sites
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replaced with Asp). Cells expressing 4A-EXO1 were severely
impaired in RPA foci formation after irradiation, similar to that
seen in cells expressing ND-EXO1 (Fig. 2a; Supplementary
Fig. 2a), and this defect was more severe than that seen with
EXO1 individually mutated at these four sites (Fig. 1e). Inter-
estingly, cells expressing 4D-EXO1 were proﬁcient in RPA foci
V5
p-SP
p-TP
IgG
V5
Actin
IP
In
pu
t
Asyn Asyn G1 S G2
+AZD
G2
IP: V5
IP
: I
gG
V5
p-SP
p-TP
IgG
V5
Actin
IP
: I
gG
D
M
SO
AZ
D
R
os
c
IP: V5
V5
p-SP
p-TP
IgG
V5
Actin
Sc
r
Sc
r
CD
K1
CD
K2
CD
K1
/2IP
: I
gG IP: V5
1 846N I
* * * * * * * *
*
* S6
39
T7
32
T8
24
S8
15
Cyclin-binding sites (RXL)
*
Candidate CDK-phosphorylation sites (S/TP)
sW
T
sW
T
rW
T
rW
T
S3
76
A
T4
75
A
S5
98
A
T6
21
A
S6
23
A
S6
25
A
S6
39
A
T7
32
A
S8
15
A
T8
24
A
N
D
25
20
15
10
5
0
N
o.
 
o
f R
PA
 fo
ci
 p
er
 c
el
l
siScr siEXO1
V5
Actin
V5
p-SP
p-TP
IgG
V5
Actin
IP
In
pu
t
rWT rWT 4A
IP
: I
gG
IP: V5
V5
p-T732
IgG
V5
Actin
IP
In
pu
t
+AZD T7
32
A
rWT
G1G2 G2
IP
: I
gG
IP: V5
siRNA
150
100
150
100
150
100
50
150
100
50
37
150
100
150
100
50
150
100
50
37
150
100
150
100
150
100
50
150
100
50
150
100
50
37
(kDa)
IP
In
pu
t
150
100
150
100
150
100
50
150
100
37
IP
In
pu
t
150
100
150
100
150
100
50
150
100
50
Figure 1 | EXO1 is phosphorylated by CDKs 1 and 2 in S and G2 phases. (a) HEK-293 cells expressing V5-EXO1 were synchronized in different phases of
the cell cycle. EXO1 was immunoprecipitated (IP) with anti-V5 antibody and western blotted with anti-phospho-Ser (p-SP) or anti-phospho-Thr (p-TP)
CDK substrate antibodies, as indicated. ‘þAZD’ indicates cells pre-treated with the CDK inhibitor AZD5438 before analysis. (b) HEK-293 cells expressing
V5-EXO1, synchronized in G2, were pre-treated with CDK inhibitors, AZD5438 or roscovitine, before analysis of EXO1 phosphorylation by IP-western.
(c) HEK-293 cells expressing V5-EXO1, with siRNA-mediated depletion of CDK1 and/or CDK2, were synchronized in G2 and EXO1 phosphorylation status
determined by IP-western. Scr denotes scrambled siRNA used as a control. (d) Schematic of human EXO1 with asterisks indicating location of S/TP sites.
Sites determined in this study to be important for resection are numbered. Locations of cyclin-binding (Cy) sites are indicated by solid triangles. N-terminal
(N) and internal (I) catalytic domains are indicated. (e) U2OS cells were depleted of endogenous EXO1 using siRNA and complemented with siRNA-
resistant wild-type EXO1 (rWT) or EXO1 individually mutated at S/TP sites, as indicated. Cells were screened for resection defects by quantifying
IR-induced RPA foci. Average numbers of RPA foci per cell are plotted after subtracting background (average numbers of foci in mock-irradiated cells). Cells
expressing siRNA-sensitive EXO1 (sWT) or siRNA-resistant nuclease dead EXO1 (ND) served as resection-defective controls (dashed line demarcates
basal levels of RPA foci in these cells). Western blot shows comparable expression of EXO1 mutants and depletion of sWT-EXO1 by siRNA. (f) HEK-293
cells expressing WT-EXO1 or EXO1 with all four C-terminal S/TP sites mutated to Ala (4A-EXO1) were synchronized in G2, and EXO1 phosphorylation
status determined by IP-western. (g) HEK-293 cells expressing WT-EXO1 or EXO1 with a T732A point mutation were synchronized in G1 or G2, as
indicated, and EXO1 phosphorylation at the T732 site was determined by IP-western with anti-phospho-EXO1 (p-T732) antibody. All experiments were
replicated three times. Error bars depict s.e.m. See also Supplementary Fig. 1.
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Figure 2 | Phosphorylation of EXO1 by CDKs promotes DNA end resection. (a) U2OS cells were depleted of endogenous EXO1 using siRNA and
complemented with siRNA-sensitive wild-type EXO1 (sWT) or siRNA-resistant wild-type EXO1 (rWT), non-phosphorylatable mutant EXO1 (4A) or phospho-
mimic EXO1 with all four C-terminal S/TP sites replaced with Asp (4D), as indicated. Representative images of mock-irradiated or irradiated (IR) cells
immunostained with anti-RPA antibody (red) are shown. Nuclei were stained with 40 ,6-diamidino-2-phenylindole (blue). Plot shows average numbers of RPA
foci per cell after subtracting background (average numbers of foci in mock-irradiated cells). (b) Representative images of mock-irradiated or irradiated cells
immunostained for BrdU/ssDNA foci (red) are shown. Plot shows percentages of cells with more than 10 BrdU foci per nucleus after background subtraction.
(c) Representative images of irradiated cells co-immunoﬂuorescence stained with anti-cyclin A antibody (red) and anti-Rad51 antibody (green) are shown.
Average numbers of Rad51 foci for cyclin A-positive (S/G2) nuclei are plotted after background subtraction. (d–f) Cells expressing rWTor 4D-EXO1 were pre-
treated with CDK inhibitors (AZD5438 or roscovitine) or with DMSO as control, irradiated and assayed for RPA, BrdU or Rad51 foci, as indicated. Scale bar,
10mm (for all images). All experiments were replicated three times. Error bars depict s.e.m. See also Supplementary Fig. 2.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4561
4 NATURE COMMUNICATIONS | 5:3561 | DOI: 10.1038/ncomms4561 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
formation and actually exhibited higher numbers of foci than cells
expressing wild-type EXO1 (rWT-EXO1). The impairment in
RPA foci formation on expression of 4A-EXO1 was clearly due to
impaired DNA resection, directly quantiﬁed as IR-induced BrdU/
ssDNA foci, as described previously20 (Fig. 2b). The resection
defect in cells expressing 4A-EXO1 resulted in a decrease in IR-
induced Rad51 foci17 in S/G2 cells (cyclin A positive28),
suggesting attenuated HR (Fig. 2c). The observed impairments
in resection and HR were not due to perturbations of the cell
cycle as assessed by ﬂow cytometry (Supplementary Fig. 2b) or
attenuation of the nuclease activity of 4A-EXO1 as assessed by
in vitro nuclease assay (Supplementary Fig. 2c).
Pharmacological inhibition of CDKs using AZD5438 or
roscovitine severely impaired resection and HR (Fig 2d–f;
Supplementary Fig. 2d–f). Remarkably, 4D-EXO1 could partially
override the effects of CDK inhibition. In accord with these
results, expression of 4D-EXO1 could partially rescue decreased
IR-induced RPA foci formation in CtIP- or DNA2-depleted cells
(Supplementary Fig. 2g,h) demonstrating that phosphorylation of
EXO1 is sufﬁcient to trigger substantial resection in human cells,
and therefore would be a step over which the cell must exercise
stringent control as it traverses the cell cycle.
Interaction of EXO1 and CDKs is obligatory for DNA end
resection. CDK–cyclin complexes, especially CDK2–cyclin A,
bind to their substrates in a bipartite manner, with CDK binding
to its phosphorylation site(s) and cyclin binding to distal RXL
motif(s) called Cy23,29. We found that V5-EXO1 interacted with
CDK1, CDK2, cyclin A and cyclin B in co-immunoprecipitation
(co-IP) experiments (Fig. 3a), and these interactions were also
seen by IP of endogenous EXO1 (Supplementary Fig. 3a). EXO1
bears two Cy motifs (at positions 204–206 and 293–295; Fig. 1d).
Mutation of both Cy motifs to Ala (CyMut) weakened interactions
with CDK1 and particularly affected binding to CDK2 (Fig. 3a), as
conﬁrmed by reverse co-IP (Supplementary Fig. 3b). Importantly,
mutation of both Cy motifs dramatically reduced EXO1
phosphorylation, as assessed by IP-westerns with both CDK
substrate antibodies and the newly generated site-speciﬁc anti-p-
T732 antibody (Fig. 3b). Cy mutations also resulted in severe
defects in RPA, BrdU/ssDNA and Rad51 foci formation (Fig 3c–e;
Supplementary Fig. 3c–f). Strikingly, the resection and HR defects
caused by Cy mutations could be rescued, at least partially, by
phospho-mimic substitutions at the four C-terminal S/TP sites
(CyMut/4D). Therefore, EXO1 interacts with CDK–cyclin
complexes via its Cy motifs, and these interactions are required
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Figure 3 | Interaction of EXO1 and CDKs is obligatory for DNA end resection. (a) HEK-293 cells expressing V5-tagged wild-type EXO1 (rWT) or EXO1
with Cy (cyclin binding) sites mutated (CyMut) were synchronized in G2. Whole-cell extracts were immunoprecipitated (IP) with anti-V5 antibody
and immunoprecipitates were probed by western blotting with the indicated antibodies. (b) HEK-293 cells expressing WT- or CyMut-EXO1 were
synchronized in G2. EXO1 was immunoprecipitated (IP) with anti-V5 antibody and western blotted with anti-phospho-Ser (p-SP) or anti-phospho-Thr
(p-TP) CDK substrate antibodies or with the site-speciﬁc anti-phospho-EXO1 (p-T732) antibody, as indicated. (c–e) U2OS cells were depleted of
endogenous EXO1 using siRNA and complemented with siRNA-sensitive wild-type EXO1 (sWT) or siRNA-resistant wild-type EXO1 (rWT), Cy-mutant
EXO1 (CyMut) or Cy-mutant EXO1 with phospho-mimic substitutions (CyMut/4D), as indicated. Cells were irradiated and assayed for RPA, BrdU/ssDNA
or Rad51 foci, as indicated. All experiments were replicated three times. Error bars depict s.e.m. See also Supplementary Fig. 3.
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for EXO1 phosphorylation and DNA end resection; however, this
requirement can be overridden by phospho-mimic substitutions
on EXO1, unequivocally demonstrating that phosphorylation of
EXO1 by CDKs is essential for resection in vivo.
EXO1 phosphorylation promotes its recruitment to DSBs.
Next, we asked whether EXO1 phosphorylation might promote
its recruitment to the sites of DSBs. We carried out live-cell
imaging of green ﬂuorescent protein (GFP)-tagged EXO1 at DNA
breaks induced focally by laser micro-irradiation, as described
before20. We have previously shown that EXO1 recruitment to
breaks is signiﬁcantly augmented in G2 relative to G1 (ref. 20).
Therefore, to exclude any cell cycle effects, all GFP-EXO1
recruitment studies were carried out in cells synchronized in G2
(Supplementary Fig. 4a). The CDK inhibitor AZD5438 attenuated
GFP-EXO1 accumulation indicating that CDK activity is
important for damage-site localization of EXO1 (Supplementary
Fig. 4b). In accord with this observation, the 4A-EXO1 mutant
showed reduced accumulation at breaks while accumulation of
4D-EXO1 was augmented relative to WT-EXO1 (Fig. 4a). In
parallel experiments, we quantiﬁed the recruitment of GFP-RPA
to the sites of laser-induced DNA lesions in real time, as
described previously20. We observed that GFP-RPA accumulation
was attenuated in cells expressing 4A-EXO1 and augmented in
cells expressing 4D-EXO1 (Supplementary Fig. 4c), indicating
reduced and increased resection, respectively. Thus,
phosphorylation of EXO1 by CDKs promotes its accumulation
at DNA breaks that positively inﬂuences the extent of resection.
EXO1 is reported to interact with other proteins that control
resection, namely, CtIP30 and BLM9. We asked whether EXO1
phosphorylation might augment its recruitment to DSBs by
facilitating some of these protein–protein interactions. We carried
out co-IPs using extracts from HEK-293 cells synchronized in G2
and expressing WT-, 4A- or 4D-EXO1 (Fig. 4b). We observed
interactions of EXO1 with CtIP and BLM but these interactions
were not affected by the 4A mutations. Interestingly, we found
that EXO1 also interacted with BRCA1, a key regulator of HR31,
and this interaction was reduced by the 4A mutations (Fig. 4b), as
conﬁrmed by reverse co-IP (Supplementary Fig. 4d). Binding to
BRCA1 was unaffected by irradiation of cells or by the presence of
ethidium bromide (Supplementary Fig. 4e); thus, it is likely that
these interactions are direct and not mediated by DNA. Notably,
the BRCA1–EXO1 interaction was cell cycle dependent, showing a
marked increase in cells synchronized in G2 (Supplementary
Fig. 4f). BRCA1 binding was also seen on IP of endogenous EXO1
(Supplementary Fig. 4g). Co-IPs with single mutants of the four S/
TP sites did not show greatly reduced BRCA1 binding, indicating
that the interaction of EXO1 with BRCA1 involves more than one
phospho-S/TP site (Supplementary Fig. 4h).
In agreement with the observed interaction of EXO1 and
BRCA1, we found that EXO1 rapidly co-localized with BRCA1 at
sites of micro-laser-induced DNA lesions (Fig. 4c). BRCA1 has
previously been shown to interact with phosphorylated CtIP and
augment its localization at DNA breaks12,13,32,33. To see whether
BRCA1 might have a similar role in EXO1 recruitment, we
generated U2OS cells with stable short hairpin RNA (shRNA)-
mediated BRCA1 knockdown and carried out live-cell imaging of
DsRed-tagged EXO1 at DSBs induced by laser micro-irradiation,
as described previously20 (Fig. 4d). We found that EXO1
recruitment was reduced in BRCA1-depleted cells, indicating a
partial dependency on BRCA1 for damage-site localization. We
reasoned that if phospho-EXO1 was dependent on BRCA1 for
recruitment to breaks, then 4D-EXO1 should not be able to
complement the HR defect of BRCA1-deﬁcient cells, although
it is capable of alleviating HR defects caused by EXO1 depletion
(Fig. 2c), mutation of Cy sites on EXO1 (Fig. 3e) or
pharmacological inhibition of CDKs (Fig. 2f). Indeed, we found
that expression of 4D-EXO1 could not correct defective Rad51
foci formation in BRCA1-depleted cells (Supplementary Fig. 4i)
or reduce induction of radial chromosome structures34 on
irradiation (Supplementary Fig. 4j). In summary, although
BRCA1 has a role in facilitating the recruitment of EXO1 to
DSBs, whether the interactions between BRCA1 and EXO1
contribute to EXO1 recruitment remains to be determined.
EXO1 phosphorylation regulates repair pathway choice. Our
results raised the possibility that phosphorylation of EXO1 by
CDKs is a novel mechanism by which the cell exercises repair
pathway choice. To address this, we used two different reporter
assays to quantify the repair of I-SceI-induced DSBs by HR17 or by
NHEJ35. Cells bearing integrated HR or NHEJ reporters were
depleted of endogenous EXO1 and complemented with siRNA-
resistant WT-, 4A- or 4D-EXO1. Expression of 4A-EXO1 resulted
in reduced levels of HR relative to WT-EXO1, while expression of
4D-EXO1 resulted in elevated levels of HR (Fig. 5a). Converse
results were obtained with the NHEJ assay where expression of
4A-EXO1 resulted in increased levels of NHEJ relative to WT-
EXO1 (Fig. 5b). The diametrically opposite effects of impaired
EXO1 phosphorylation on HR and NHEJ clearly place this
exonuclease at a pivotal point where the balance between these
two repair pathways might be ﬁne tuned by the cell.
Next, we irradiated U2OS cells expressing WT-, 4A- or 4D-
EXO1 and quantiﬁed the formation and dissolution of 53BP1 foci
in G1 (cyclin A negative) versus S/G2 (cyclin A positive28) nuclei
to evaluate the effects of phospho-mutant versus phospho-mimic
EXO1 on the overall kinetics of DSB repair (Supplementary
Fig. 5a). Depletion of EXO1 had no discernible effect on G1 cells
(Supplementary Fig. 5b) but resulted in a subtle but distinct DSB
repair defect in S/G2 cells, as seen by comparing sWT with rWT
(Fig. 5c). This defect could be corrected by expression of
4D-EXO1 but not by expression of 4A-EXO1. Consequently,
irradiated cells expressing 4A-EXO1 exhibited a striking
induction of radial chromosomes on IR (Fig. 5d), similar to
that seen in BRCA1-deﬁcient cells34 (Supplementary Fig. 4j).
Finally, cells expressing 4A-EXO1, but not those expressing 4D-
EXO1, were sensitive to IR in the G2 phase of the cell cycle
(Fig. 5e). It is important to point out that while attenuated repair
and compromised survival in 4A-EXO1-expressing cells are
clearly attributable to defective HR, the extent to which the
altered balance between NHEJ and HR contributes to these
defects remains to be elucidated. Taken together, these results
demonstrate that EXO1 phosphorylation is critical for DSB repair
in S and G2 phases, maintenance of genomic integrity and long-
term cell survival in response to DNA damage.
Discussion
It is well established that CDKs regulate repair pathway choice by
controlling the ﬁrst step in resection (initiation) by phosphor-
ylating CtIP at seven S/TP sites10–15 and NBS1 at a single site16.
The second step in resection (long-range resection) is
indispensable for successful HR3,4. Currently, it is not known
whether CDKs regulate this key step in human cells. Our results
uncover a novel mechanism by which CDKs regulate the second
step in resection by modifying EXO1, an exonuclease with critical
functions in long-range resection.
EXO1 belongs to the RAD2/XPG family of nucleases and
displays 50–30 exonuclease activity on single- and double-stranded
DNA substrates, as well as ﬂap structure-speciﬁc endonuclease
activity. EXO1 plays important roles in DNA mismatch repair
(MMR), mitotic and meiotic recombination, replication and
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telomere homoeostasis36. EXO1 is phosphorylated at S714 by
ataxia-telangiectasia mutated (ATM) in response to DSBs17 and
by ataxia-telangiectasia- and Rad3-related (ATR) in response to
replication stress26, which inﬂuences its activity and stability,
respectively. The amino-terminal 300 amino acids of EXO1
encompassing its nuclease domain are highly conserved across
species and share common sequences with other RAD2
nucleases24. In contrast, the carboxy-terminal region of EXO1
is divergent and mediates interactions with the 14-3-3 checkpoint
regulatory proteins37, the proliferating cell nuclear antigen38 and
MMR proteins such as MutSa36. In the context of MMR, it has
been proposed that the C terminus forms an unstructured
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regulatory domain that interacts with the N-terminal catalytic
domain resulting in autoinhibition of EXO1; interaction of the C
terminus with MutSa not only couples EXO1 to the MMR
machinery but also relieves inhibition of the catalytic domain24.
How EXO1 is regulated in the context of HR and whether its C
terminus plays any role in such regulation is currently not well
understood.
We ﬁnd that the C-terminal domain of EXO1 is phospho-
rylated by CDKs 1 and 2 at S639, T732, S815 and T824 during S
and G2 phases of the cell cycle. Phosphorylation of these four
sites promotes DNA end resection and DSB repair by HR,
thereby preserving chromosomal integrity and promoting
survival on DNA damage. Further bolstering the connection
between CDKs and EXO1, we ﬁnd that Cy-mutant EXO1
(defective in cyclin-CDK binding) phenocopies 4A-EXO1 (all
four phosphorylation sites mutated) in terms of resection and HR
defects. Our results indicate that phosphorylation of EXO1
promotes end resection, in part, by augmenting the localization of
EXO1 to DNA breaks possibly via interactions with BRCA1. The
BRCA1–EXO1 interaction is limited to S/G2 phases, and this
might serve to restrict resection to the post-replicative phases of
the cell cycle. As even individual mutations of these four
phosphorylation sites result in pronounced resection defects, it
is possible that, individually, these four sites have additional and
non-redundant functions that are yet to be discovered. Such a
situation exists in the regulation of CtIP by CDKs. CtIP is
phosphorylated at multiple sites by CDKs, which promote
resection in distinct ways such as facilitating interactions
with Nbs1 and phosphorylation by ATM (ref. 14), promoting
phosphorylation by ATR (refs 5,11,39) and augmenting damage-
site localization via interaction with BRCA1 (refs 12,13,15,40).
A key question for the future is to determine the extent to which
this type of regulation applies to EXO1.
With regard to the recruitment of EXO1 to DNA breaks,
BRCA1 could also promote this step indirectly by augmenting
CtIP binding40 or antagonizing 53BP1-RIF1 binding41 to DNA
ends. It is important to point out that combined mutation of all
four CDK phosphorylation sites or depletion of BRCA1
attenuates, but does not abolish, damage-site localization of
EXO1. Therefore, it is likely that BRCA1 binding is only one
mechanism by which EXO1 is recruited to DNA breaks and other
mechanism(s), perhaps involving interactions with other
resection proteins, are yet to be elucidated. In this regard, yeast
MRX and Sae2 have been reported to promote the binding of
Exo1 to DNA ends in vitro42. We too ﬁnd that EXO1 binds to
CtIP and BLM in vivo, as reported by others9,30, although binding
is not affected by the phospho-site mutations. Thus, it is plausible
that additional protein–protein interactions could serve to
stabilize EXO1 at DNA breaks independently of these four
phospho-S/TP sites. It is interesting that single mutants of EXO1,
unlike 4A-EXO1, show no or minimal loss of BRCA1 binding, yet
exhibit pronounced resection defects. Although we cannot rule
out subtle but critical BRCA1 interaction defects of the single
EXO1 mutants that would not be revealed by co-IPs, this
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observation supports the hypothesis that additional, non-
redundant mechanisms contribute to the resection defects of
individual EXO1 mutants. Elucidating additional functions for
the identiﬁed phosphorylation sites on EXO1 is an important
task for the future, and our study sets the stage for investigating
such mechanisms. Finally, our results demonstrating regulation
of long-range resection by CDKs in human cells have some
precedence in yeast where Cdk1-dependent Dna2 phospho-
rylation has been shown to regulate DNA end resection43.
In summary, our ﬁndings indicate that phosphorylation of
EXO1 by CDKs in S/G2 phases stimulates resection, in part, by
promoting EXO1 accumulation at DSBs, and regulation of long-
range resection in this manner is critical for repair pathway
choice, maintenance of genomic integrity and long-term survival
in the face of genomic insults.
Methods
Cell culture and CDK inhibitor treatments. U2OS and HEK-293 cells (obtained
from the American Type Culture Collection) were maintained in a-MEM and
DMEM medium, respectively, supplemented with 10% fetal bovine serum and
penicillin/streptomycin in a humidiﬁed atmosphere with 5% CO2. A U2OS line
with stable shRNA-mediated knockdown of BRCA1 was generated by transfection
with a pGIPZ vector (50-TATGTGGTCACACTTTGTG-30; No.: V2LHS_254648,
Thermo Scientiﬁc) using Lipofectamine2000 (Invitrogen) followed by selection and
continued maintenance in puromycin (1mgml 1, Invitrogen). Control cells were
generated by transfection with a pGIPZ vector expressing scrambled shRNA
(No.: RHS4346, Thermo Scientiﬁc). For CDK inhibition, cells were incubated with
2 mM AZD5438 (Selleck) or 10mM roscovitine (Sigma) for 5 h before cells were
harvested or irradiated.
Cell cycle synchronization and ﬂow cytometry. HEK-293 cells were synchro-
nized in G1 by treatment with aphidicolin (2 mgml 1, Sigma) for 16 h and then
released into regular media for either 5 h (S phase) or 10 h (G2 phase)19.
Alternatively, HEK-293 cells were synchronized in late G2 by treatment with
nocodazole (100 ngml 1, Sigma) for 16 h. Cell cycle stage was determined by ﬂow
cytometry using a BD CYTOMICS FC500 Flow Cytometer (Becton, Dickinson
and Company).
Cloning and mutagenesis. EXO1b was subcloned from Flag2-EXO1 (ref. 17) into
pDONR221 (Invitrogen) using the Gateway BP Clonase II enzyme mix
(Invitrogen). Site-directed mutagenesis of EXO1 was carried out using the
QuikChange II XL Site-Directed Mutagenesis kit (Stratagene); see Supplementary
Table 1 for primer sequences. EXO1 was then transferred to pLenti6.3/V5-DEST
(Invitrogen) for C-terminal V5-tagged fusion protein expression.
Transfection of cells. Depletion of EXO1 or CDKs was carried out by transfection
with appropriate siRNAs (Supplementary Table 2; Invitrogen) using electropora-
tion (Amaxa) for U2OS cells and Lipofectamine2000 (Invitrogen) for HEK-293
cells; cells were harvested 48 h later to verify knockdown by western blotting. Cells
were transfected with scrambled siRNA as controls. For expression of tagged
proteins, cells were transfected with the appropriate expression plasmid and har-
vested after 24–48 h. For ectopic expression of EXO1 in cells with knockdown of
endogenous EXO1 or CDKs, cells were transfected with the expression plasmid
24 h after siRNA transfection.
Western blotting and antibodies. Nuclear extracts for western blotting were
prepared by re-suspending cell pellets in hypotonic lysis buffer (10mM Tris–HCl
pH 7.5, 1.5mM MgCl2, 5mM KCl, protease and phosphatase inhibitors), followed
by nuclear extraction buffer (50mM Tris–HCl pH 7.5, 0.5M NaCl, 2mM EDTA,
10% sucrose, 10% glycerol, protease and phosphatase inhibitors)19. The following
primary antibodies were used: V5 (Invitrogen), Phospho-(Thr) CDK substrate,
phospho-(Ser) CDK substrate, CHK1, phospho-CHK1 (S317), phospho-CHK2
(T68) (Cell Signaling), CDK1 (C-19), CDK2 (H-298, D-12), Rad51 (H-92), cyclin
B1 (H-433), 53BP1 (H-300; Santa Cruz), actin (Sigma), RPA (Calbiochem), BrdU
(Becton, Dickinson and Company), cyclin A (6E6), GFP (Abcam), BRCA1, EXO1
monoclonal (ThermoFisher), EXO1 polyclonal, CtIP, BLM, CHK2 (Bethyl), DsRed
(Clontech) and Ku80 (a kind gift from Dr BP Chen). The following secondary
antibodies were used: horseradish peroxidase-conjugated secondary antibodies
(Bio-Rad) and Alexa488/568/647-conjugated secondary antibodies (Invitrogen).
Antibody dilutions and catalogue numbers are provided in Supplementary Table 3.
Rabbit polyclonal phospho-speciﬁc antibody against p-T732 of EXO1 was
generated by Abmart using the phospho-peptide NH2-Cys-FSKKD(pT)PLRNK-
COOH, where pT indicates phospho-Thr. Uncropped scans of western blots are
shown in Supplementary Fig. 6.
Immunoprecipitation. Whole-cell extracts were prepared in lysis buffer (20mM
Tris–HCl pH 7.5, 80mM NaCl, 2mM EDTA, 10% glycerol, 0.2% NP-40) with
additional protease and phosphatase inhibitors. Antibodies were bound to Dyna-
beads (Invitrogen) and beads were incubated overnight with cell extracts, following
the manufacturer’s protocol. Beads were washed extensively in lysis buffer and then
boiled in 1 SDS loading buffer before western blotting. Normal mouse IgG
(Santa Cruz) was used for control immunoprecipitations.
Irradiation of cells. Cells were irradiated with gamma rays from a caesium source
(JL Shepherd and Associates). For laser irradiation, cells were pre-sensitized by
overnight incubation with BrdU (10 mgml 1) and then micro-irradiated with a
pulsed nitrogen laser (Spectra-Physics; 365 nm, 10Hz) with output set at 70% of
the maximum20. Cells were maintained at 37 C in 35mm glass-bottom culture
dishes (MatTek Cultureware) during micro-irradiation and image acquisition; the
growth medium was replaced by CO2-independent medium (Invitrogen) before
irradiation.
Immunoﬂuorescence staining. Cells were seeded onto glass chamber slides
(Lab-Tek) and immunostained with anti-RPA antibody or co-immunostained with
anti-Rad51 and anti-cyclin A antibodies 3 h after irradiation with 6Gy. Cells were
ﬁxed with 4% paraformaldehyde/PBS and permeabilized with 0.5% Triton X-100
before incubation with antibodies19. To obtain clear RPA foci, cells were subject to
in situ fractionation44. The average number of RPA foci per nucleus or mean
Rad51 foci for cyclin A-positive (S/G2) nuclei28 was determined after scoring at
least 50 nuclei and subtracting background (average numbers of foci in mock-
irradiated cells). For quantifying DSB repair kinetics, cells were co-immunostained
with anti-53BP1 and anti-cyclin A antibodies at different time points post
irradiation (1Gy), as described previously35. The average numbers of 53BP1 foci
for cyclin A-positive (S/G2) and cyclin A-negative (G1) nuclei were determined
after scoring at least 50 nuclei and subtracting background. Images were captured
using a Leica DH5500B ﬂuorescence microscope ( 40 objective lens) coupled to a
Leica DFC340 FX camera using Leica Application Suite v3 acquisition software.
BrdU/ssDNA assay. Cells grown in the presence of 10 mM BrdU (Sigma) for 16 h
were irradiated with 10Gy of gamma rays and ﬁxed 1 h after irradiation. Cells were
immunoﬂuorescence stained with anti-BrdU antibody under non-denaturing
conditions (to detect BrdU incorporated into ssDNA)20. For clarifying BrdU/
ssDNA foci, cells were subject to in situ fractionation44. The percentage of
BrdU-positive cells (cells with 10 or more foci) was determined after scoring at
least 50 nuclei and subtracting background.
HR and NHEJ assays. To measure HR, GFP expression in MCF7 cells with an
integrated DR-GFP reporter was quantiﬁed by ﬂow cytometry17. To measure NHEJ,
red ﬂuorescent protein (RFP) expression in HEK-293 cells with an integrated
GFP-to-RFP reporter was quantiﬁed by ﬂow cytometry. For both assays, cells were
co-transfected with siRNA against endogenous EXO1 and the V5-EXO1 expression
plasmid; after 24 h, cells were transfected with an I-SceI plasmid, and GFP or RFP
expression was quantiﬁed by ﬂow cytometry after an additional 72 h. GFPþ or
RFPþ frequencies were corrected for transfection efﬁciencies (measured
simultaneously by parallel transfection with a wild-type GFP expression vector).
Metaphase chromosome preparations. Cells were irradiated with 6Gy of
gamma rays. Colcemid (Sigma), along with 1mM caffeine (Sigma) to bypass G2/M
arrest, was added at 8 h post IR. Metaphase chromosome spreads were prepared
after 16 h and scored for triradial and quadriradial chromosomes45.
Live-cell imaging combined with laser micro-irradiation. Cells were transfected
with GFP-EXO1, GFP-RPA or DsRed-EXO1 constructs, laser micro-irradiated and
time-lapse imaged, and the ﬂuorescence intensities of micro-irradiated areas were
plotted after background subtraction (ﬂuorescence intensities of unirradiated
areas)20,46. In brief, cells were irradiated and live-cell images were taken using a
pulsed nitrogen laser (Spectra-Physics; 365 nm, 10Hz) coupled to a Carl Zeiss
Axiovert 200M microscope ( 63 oil immersion objective). Fluorescence
intensities were determined using Axiovision software v4.8 that converts signal
intensities of accumulated GFP or DsRed into numerical values (arbitrary units).
The ﬂuorescence intensity of an unirradiated region was subtracted from the
ﬂuorescence intensity of the micro-irradiated area for each nucleus at each time
point to compensate for nonspeciﬁc ﬂuorescence bleaching during repeated image
acquisition. Mean value of the ﬂuorescence intensities for each time point was
calculated from at least 40 independent measurements. Total increase in
ﬂuorescence signal (after background subtraction) was plotted versus time.
Colony formation assays. Cells were synchronized in G2 and irradiated with the
indicated doses of gamma rays. After 4 h, cells were plated in triplicate onto 60mm
dishes (1,000 cells per dish). Surviving colonies were stained with crystal violet
B10–14 days later.
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